U54AG089335
Cooperative Agreement
Overview
Grant Description
Human Virome Characterization Center for the Oral-Gut-Brain Axis - Overall-Project Summary/Abstract
The NIH Human Microbiome Project has redefined our understanding of the human bacteriome, opening new avenues of research in the biomedical and behavioral sciences and improving healthcare delivery.
However, the human virome remains largely unexplored.
In response to this gap, the NIH Human Virome Program (HVP) offers the opportunity to uncover the spectrum of “healthy” viromes across the lifespan, facilitating identification of alterations associated with disease and further advancing biomedical research and healthcare delivery.
Toward this goal, we propose to establish this Human Virome Characterization Center (HVCC) for the Oral–Gut–Brain Axis, a known functional unit with a central role in human health.
Informed by our team’s long-standing expertise studying these organs and their interconnected physiology, we will create an organizational hub for virome study, leveraging multiple unique and diverse cohorts.
Our goal is to identify and characterize the viruses comprising the human virome across the Oral–Gut–Brain Axis, providing accurate estimates of its richness and complexity in healthy cohorts across the life/healthspan.
In support of this goal, we bring together investigators at several institutions, including UCLA, Baylor College of Medicine, Mayo Clinic, Penn State, USC, UCSD, NIH/NIDCR, with broad experience successfully guiding large NIH programs.
We will establish five interacting cores—administrative, biospecimen collection, biospecimen analysis, data analysis and submission, and ethical, legal, and social implications (ELSI)—that will work together to identify the viromes in numerous patient cohorts diverse in age, race/ethnicity, each derived from the three target organs.
Our cores have interdisciplinary expertise across key areas, including virome/microbiome sequencing, biomedical informatics/data science, and patient recruitment/tissue banking, and will be tasked with handling multiple data types (virome/microbiome, genomic, neuroimaging) to support the broad aims of our HVCC.
The biospecimen collection core will leverage prospective cohorts and retrospective biospecimen banks at UCLA, Mayo Clinic, and NIH/NIDCR, as well as several future cohort opportunities (All of Us, Together for Change, AIIMS/India).
Our biospecimen analysis core will use cutting-edge technologies to sequence the viromes in our biospecimens, and our data analysis and submission core will analyze the data we collect using innovative bioinformatics, data science, and machine-learning tools to uncover clinical, physiologic, and genetic interactions that shape the human virome.
The ELSI core will provide policies and guidance and conduct original research to explore the ELSI of this work.
The administrative core will bridge the patient cohort teams with the supporting cores to ensure seamless operation and coordination with the broader HVP.
Our cores are designed to maximize the integration and sharing of ideas through dynamic, contemporary communication methods, promoting refinement and dissemination of best practices between our group and the wider scientific community.
In doing so, this HVCC will provide a unified framework to broadly advance our understanding of the Oral–Gut–Brain virome toward improving human health.
The NIH Human Microbiome Project has redefined our understanding of the human bacteriome, opening new avenues of research in the biomedical and behavioral sciences and improving healthcare delivery.
However, the human virome remains largely unexplored.
In response to this gap, the NIH Human Virome Program (HVP) offers the opportunity to uncover the spectrum of “healthy” viromes across the lifespan, facilitating identification of alterations associated with disease and further advancing biomedical research and healthcare delivery.
Toward this goal, we propose to establish this Human Virome Characterization Center (HVCC) for the Oral–Gut–Brain Axis, a known functional unit with a central role in human health.
Informed by our team’s long-standing expertise studying these organs and their interconnected physiology, we will create an organizational hub for virome study, leveraging multiple unique and diverse cohorts.
Our goal is to identify and characterize the viruses comprising the human virome across the Oral–Gut–Brain Axis, providing accurate estimates of its richness and complexity in healthy cohorts across the life/healthspan.
In support of this goal, we bring together investigators at several institutions, including UCLA, Baylor College of Medicine, Mayo Clinic, Penn State, USC, UCSD, NIH/NIDCR, with broad experience successfully guiding large NIH programs.
We will establish five interacting cores—administrative, biospecimen collection, biospecimen analysis, data analysis and submission, and ethical, legal, and social implications (ELSI)—that will work together to identify the viromes in numerous patient cohorts diverse in age, race/ethnicity, each derived from the three target organs.
Our cores have interdisciplinary expertise across key areas, including virome/microbiome sequencing, biomedical informatics/data science, and patient recruitment/tissue banking, and will be tasked with handling multiple data types (virome/microbiome, genomic, neuroimaging) to support the broad aims of our HVCC.
The biospecimen collection core will leverage prospective cohorts and retrospective biospecimen banks at UCLA, Mayo Clinic, and NIH/NIDCR, as well as several future cohort opportunities (All of Us, Together for Change, AIIMS/India).
Our biospecimen analysis core will use cutting-edge technologies to sequence the viromes in our biospecimens, and our data analysis and submission core will analyze the data we collect using innovative bioinformatics, data science, and machine-learning tools to uncover clinical, physiologic, and genetic interactions that shape the human virome.
The ELSI core will provide policies and guidance and conduct original research to explore the ELSI of this work.
The administrative core will bridge the patient cohort teams with the supporting cores to ensure seamless operation and coordination with the broader HVP.
Our cores are designed to maximize the integration and sharing of ideas through dynamic, contemporary communication methods, promoting refinement and dissemination of best practices between our group and the wider scientific community.
In doing so, this HVCC will provide a unified framework to broadly advance our understanding of the Oral–Gut–Brain virome toward improving human health.
Funding Goals
TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE. THE NATIONAL INSTITUTE ON AGING HAS ESTABLISHED PROGRAMS TO PURSUE THESE GOALS. THE DIVISION OF AGING BIOLOGY EMPHASIZES UNDERSTANDING THE BASIC BIOLOGICAL PROCESSES OF AGING. THE DIVISION OF GERIATRICS AND CLINICAL GERONTOLOGY SUPPORTS RESEARCH TO IMPROVE THE ABILITIES OF HEALTH CARE PRACTITIONERS TO RESPOND TO THE DISEASES AND OTHER CLINICAL PROBLEMS OF OLDER PEOPLE. THE DIVISION OF BEHAVIORAL AND SOCIAL RESEARCH SUPPORTS RESEARCH THAT WILL LEAD TO GREATER UNDERSTANDING OF THE SOCIAL, CULTURAL, ECONOMIC AND PSYCHOLOGICAL FACTORS THAT AFFECT BOTH THE PROCESS OF GROWING OLD AND THE PLACE OF OLDER PEOPLE IN SOCIETY. THE DIVISION OF NEUROSCIENCE FOSTERS RESEARCH CONCERNED WITH THE AGE-RELATED CHANGES IN THE NERVOUS SYSTEM AS WELL AS THE RELATED SENSORY, PERCEPTUAL, AND COGNITIVE PROCESSES ASSOCIATED WITH AGING AND HAS A SPECIAL EMPHASIS ON ALZHEIMER'S DISEASE. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding Agency
Place of Performance
Los Angeles,
California
90095
United States
Geographic Scope
Single Zip Code
Los Angeles University Of California was awarded
Human Virome Center: Advancing Oral-Gut-Brain Axis Research for Health
Cooperative Agreement U54AG089335
worth $4,399,997
from the National Institute of Allergy and Infectious Diseases in February 2025 with work to be completed primarily in Los Angeles California United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.310 Trans-NIH Research Support.
The Cooperative Agreement was awarded through grant opportunity Human Virome Characterization Centers (U54 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 3/20/25
Period of Performance
2/1/25
Start Date
1/31/30
End Date
Funding Split
$4.4M
Federal Obligation
$0.0
Non-Federal Obligation
$4.4M
Total Obligated
Activity Timeline
Transaction History
Modifications to U54AG089335
Additional Detail
Award ID FAIN
U54AG089335
SAI Number
U54AG089335-521760374
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NN00 NIH National Insitute on Aging
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
RN64EPNH8JC6
Awardee CAGE
4B557
Performance District
CA-36
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Modified: 3/20/25